Associated Papers
Next generation sequencing and genomic mapping: towards precision molecular diagnosis of lung cancer in Morocco.
Morjani O et al.
The Pan African Medical Journal, 2024
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › ERBB2_mutations
RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC.
Wang Q et al.
Frontiers in Oncology, 2023
37441425 (PubMed )
Supplement: Table_3.xlsx › mutations
HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma.
Jia Z et al.
Translational Lung Cancer Research, 2021
Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
Fan Y et al.
Molecular Oncology, 2020
32478891 (PubMed )
Supplement: MOL2-14-1731-s002.xlsx › Sheet1
Select a paper to view details